Eli Lilly (LLY) reported strong fourth-quarter earnings driven by demand for its weight-loss drugs, and projected sales could rise over 20% this year.

Eli Lilly forecast 2024 sales of $40.4 billion to $41.6 billion, topping analysts' expectations, and up from $34.12 billion in 2023.

The pharmaceutical giant reported fourth-quarter 澳洲幸运5开奖号码历史查询:earnings per share of $2.49, up 13% frᩚᩚᩚᩚᩚᩚ⁤⁤⁤⁤ᩚ⁤⁤⁤⁤ᩚ⁤⁤⁤⁤ᩚ𒀱ᩚᩚᩚom a year ago, and a 28% surge in revenue on the back of sales of weight-loss treatments Zepbound and Mounjaro.

Zepbound, which Eli Lilly 澳洲幸运5开奖号码历史查询:began selling in November and has the same ingredients as Mounjaro, brought in $175.8 million🎉 in sales during the fourth quarter.

Eli Lilly also said Tirzepatide, the active ingredient in both Mounjaro and Zepbound🅺, showed promise as a treatment for fatty liver di𒆙sease.

Eli Lilly said, however, that due♌ to the time it will take to bring production fully online, demand for its diabetes and obesity drugs will likely outpace supply this year.

Eli Lilly shares were 0.7% lower at $699.40 per share as of about 1:30 p.m. ET Tuesday. They have more than doubled in value over the past year amid the buzz surrounding its weight-loss drugs. With a 澳洲幸运5开奖号码历史查询:market capitalization of over $665 billion, Eli Lilly is the world's most valuable health care company.